Mankind Pharma share price
You have to be logged in to add this to Watchlist.- ₹2,291.55(-1.34%)June 20, 2025 15:29:21 PM IST
- NSE
- BSE
- Vol : 1.23M (NSE + BSE)Last 20 day avg : 394.38 K
Mankind Pharma is trading -1.34% lower at Rs 2,291.55 as compared to its last closing price. Mankind Pharma has been trading in the price range of 2,325.10 & 2,282.85. Mankind Pharma has given -19.28% in this year & -2.71% in the last 5 days. Mankind Pharma has TTM P/E ratio 49.03 as compared to the sector P/E of 22.66.There are 16 analysts who have initiated coverage on Mankind Pharma. There are 5 analysts who have given it a strong buy rating & 6 analysts have given it a buy rating. 2 analysts have given the stock a sell rating.The company posted a net profit of 420.77 Crores in its last quarter.Listed peers of Mankind Pharma include Hyundai Motor India (5.05%), Bajaj Housing Finance (1.31%), Mankind Pharma (-1.34%).The Mutual Fund holding in Mankind Pharma was at 7.67% in 31 Mar 2025. The MF holding has decreased from the last quarter. The FII holding in Mankind Pharma was at 12.92% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
- 1 D
- 5 D
- 1 M
- 3 M
- 6 M
- 1 Y
- 5 Y
- MAX
Updated on Jun 20, 2025, 07:58 PM UTC
- Dividend YieldLower than industry0.00Annual dividends as a percentage of the stock price.
- P/B6.69The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/EHigher than historical values47.19Price-to-earnings ratio based on trailing 12-month earnings
- Debt To EquityHigher than industry0.59The debt-to-equity ratio, indicating a company's financial leverage.
- Beta-Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable
The company's profit declined by 10.71% year-on-year during the March quarter, dropping from Rs 471.24 crore to Rs 420.77 crore- The debt to equity of the company is higher than the industry median
- Company can comfortably pay off its interest obligations with its earnings
- R1
- 2,579.72
- R2
- 2,685.78
- R3
- 2,825.57
- S1
- 2,333.87
- S2
- 2,194.08
- S3
- 2,088.02
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Hyundai Motor India | Bullish | 2,006.05 | 5.05 | 1,63,217.76 | 27.82 | 9.63 | - | 3.58 |
| Bajaj Housing Finance | Moderately Bearish | 119.50 | 1.31 | 99,571.40 | 43.83 | 5.03 | - | 411.27 |
| Mankind Pharma | Bearish | 2,291.55 | -1.34 | 94,568.68 | 48.04 | 6.79 | - | 38.66 |
| Ntpc Green Energy | Moderately Bullish | 110.30 | 6.01 | 92,942.42 | 159.22 | 4.87 | - | 100.45 |
| Swiggy | Moderately Bullish | 390.10 | 4.22 | 97,277.16 | - | 8.92 | - | 12.89 |
- Promoter(s) holds a high stake in the company at 72.70%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding has decreased by 0.42 percentage points from previous quarter
- Mutual Funds holding has decreased by 0.16 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-21 | Audited Results |
| 2025-01-23 | Quarterly Results |
| 2024-11-05 | Quarterly Results |
| 2024-07-31 | Quarterly Results |
| 2024-05-15 | Audited Results & Others |
- Industry
- ISININE634S01028
- BSE Code543904
- NSE CodeMANKIND
Mankind Pharma is trading at 2291.55 as on Fri Jun 20 2025 09:59:21. This is -1.34% lower as compared to its previous closing price of 2322.75.
The market capitalization of Mankind Pharma is 94568.68 Cr as on Fri Jun 20 2025 09:59:21.
The average broker rating on Mankind Pharma is Buy. The breakup of analyst rating is given below -
- 5 analysts have given a strong buy rating
- 6 analysts have given a buy rating
- 3 analysts have given a hold rating
- 2 analysts have given a sell rating
- 0.00 analysts have given a strong sell rating
The 52 wk high for Mankind Pharma is 3050.00 whereas the 52 wk low is 1910.10
Mankind Pharma can be analyzed on the following key metrics -
- TTM P/E: 49.03
- Sector P/E: 22.66
- Dividend Yield: 0.00%
- D/E ratio: 0.59
Mankind Pharma reported a net profit of 1990.96 Cr in 2025.
The Mutual Fund Shareholding was 7.67% at the end of 31 Mar 2025.